$66.69
0.10.15%
At Close: -
$66.45
-0.24-0.36%
After Hours: 7:43 PM EDT
15 minutes delayed
want to know what
the Bulls & Bears Say?
Gilead Sciences (NASDAQ:GILD) 주식, 분석가 평가, 목표 가격, 예측
Gilead Sciences Inc의 합의된 목표 주가는 93개의 최신 애널리스트 평가를 살펴보고 설정되었습니다. 마지막 3개의 애널리스트 평가는 7월 1, 2024, 6월 20, 2024 및 6월 14, 2024에 RBC Capital, Baird 및 RBC Capital에서 발표되었습니다. RBC Capital, Baird 및 RBC Capital 사이의 평균 목표 주가는 $76로, 이러한 3개의 애널리스트 평가에서 Gilead Sciences Inc에 대한 암시된 14.37% upside가 있습니다.
추천을 하는 애널리스트 회사들1
RBC Capital
Baird
Barclays
TD Cowen
Morgan Stanley
1애널리스트 평가로부터 계산됨
Gilead Sciences에 대한 애널리스트 평점
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | Buy Now | 11.36% | RBC Capital | Brian Abrahams | $74 → $74 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/20/2024 | Buy Now | 20.39% | Baird | Brian Skorney | $80 → $80 | Maintains | Neutral | Get Alert |
| 06/14/2024 | Buy Now | 11.36% | RBC Capital | Brian Abrahams | $74 → $74 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 04/29/2024 | Buy Now | 14.37% | Barclays | Carter Gould | $80 → $76 | Maintains | Equal-Weight | Get Alert |
| 04/26/2024 | Buy Now | 27.91% | TD Cowen | Tyler Van Buren | $90 → $85 | Maintains | Buy | Get Alert |
| 04/26/2024 | Buy Now | 17.38% | Morgan Stanley | Matthew Harrison | $80 → $78 | Maintains | Equal-Weight | Get Alert |
| 04/26/2024 | Buy Now | 11.36% | RBC Capital | Brian Abrahams | $76 → $74 | Maintains | Sector Perform | Get Alert |
| 04/26/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 04/24/2024 | Buy Now | 3.83% | HSBC | Morten Herholdt | → $69 | Upgrade | Reduce → Hold | Get Alert |
| 04/19/2024 | Buy Now | 58.01% | Oppenheimer | Hartaj Singh | $105 → $105 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 12.86% | UBS | Colin Bristow | $81 → $75 | Maintains | Neutral | Get Alert |
| 03/04/2024 | Buy Now | 17.38% | Wells Fargo | Mohit Bansal | $84 → $78 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 35.44% | Mizuho | Salim Syed | $101 → $90 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 23.4% | Truist Securities | Robyn Karnauskas | $91 → $82 | Downgrade | Buy → Hold | Get Alert |
| 02/14/2024 | Buy Now | 12.86% | RBC Capital | Brian Abrahams | $76 → $75 | Maintains | Sector Perform | Get Alert |
| 02/12/2024 | Buy Now | 20.39% | Barclays | Carter Gould | $85 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | Buy Now | 58.01% | Oppenheimer | Hartaj Singh | $115 → $105 | Maintains | Outperform | Get Alert |
| 02/07/2024 | Buy Now | 17.38% | Cantor Fitzgerald | Olivia Brayer | $80 → $78 | Maintains | Neutral | Get Alert |
| 02/07/2024 | Buy Now | 14.37% | RBC Capital | Brian Abrahams | $78 → $76 | Maintains | Sector Perform | Get Alert |
| 02/07/2024 | Buy Now | 26.41% | Wells Fargo | Mohit Bansal | $90 → $84 | Maintains | Equal-Weight | Get Alert |
| 01/23/2024 | Buy Now | 27.91% | Barclays | Carter Gould | $82 → $85 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | Buy Now | 15.87% | RBC Capital | Brian Abrahams | $78 → $77 | Maintains | Sector Perform | Get Alert |
| 11/09/2023 | Buy Now | 12.86% | Deutsche Bank | James Shin | → $75 | Initiates | → Hold | Get Alert |
| 09/08/2023 | Buy Now | 42.96% | B of A Securities | Geoff Meacham | $88 → $95 | Upgrade | Neutral → Buy | Get Alert |
| 09/06/2023 | Buy Now | 36.94% | Truist Securities | Robyn Karnauskas | → $91 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | Buy Now | 6.84% | HSBC | Morten Herholdt | → $71 | Initiates | → Reduce | Get Alert |
| 08/04/2023 | Buy Now | 32.43% | Morgan Stanley | Matthew Harrison | $86 → $88 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 26.41% | RBC Capital | Brian Abrahams | $83 → $84 | Maintains | Sector Perform | Get Alert |
| 07/24/2023 | Buy Now | 50.49% | Piper Sandler | Joseph Catanzaro | $105 → $100 | Maintains | Overweight | Get Alert |
| 07/24/2023 | Buy Now | 20.39% | Cantor Fitzgerald | Olivia Brayer | → $80 | Reiterates | Neutral → Neutral | Get Alert |
| 07/24/2023 | Buy Now | 20.39% | Barclays | Carter Gould | $81 → $80 | Maintains | Equal-Weight | Get Alert |
| 07/20/2023 | Buy Now | 20.39% | Cantor Fitzgerald | Olivia Brayer | $85 → $80 | Maintains | Neutral | Get Alert |
| 07/11/2023 | Buy Now | 29.42% | Morgan Stanley | Matthew Harrison | $86 → $86 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/11/2023 | Buy Now | 21.89% | Barclays | Carter Gould | $84 → $81 | Maintains | Equal-Weight | Get Alert |
| 06/23/2023 | Buy Now | 32.43% | RBC Capital | Brian Abrahams | $88 → $88 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/16/2023 | Buy Now | 50.49% | BMO Capital | Evan Seigerman | $90 → $100 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/01/2023 | Buy Now | 29.42% | Morgan Stanley | Matthew Harrison | $85 → $86 | Maintains | Equal-Weight | Get Alert |
| 04/28/2023 | Buy Now | 32.43% | RBC Capital | Brian Abrahams | $87 → $88 | Maintains | Sector Perform | Get Alert |
| 04/28/2023 | Buy Now | 58.01% | Piper Sandler | Joseph Catanzaro | → $105 | Assumes | → Overweight | Get Alert |
| 04/25/2023 | Buy Now | 30.92% | RBC Capital | Brian Abrahams | → $87 | Reiterates | → Sector Perform | Get Alert |
| 04/12/2023 | Buy Now | 27.91% | Morgan Stanley | Matthew Harrison | $81 → $85 | Maintains | Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | 29.42% | RBC Capital | Brian Abrahams | $87 → $86 | Maintains | Sector Perform | Get Alert |
| 02/14/2023 | Buy Now | 51.99% | Mizuho | Salim Syed | $88 → $101 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 36.94% | SVB Leerink | David Risinger | $81 → $91 | Maintains | Market Perform | Get Alert |
| 02/03/2023 | Buy Now | 21.89% | Morgan Stanley | Matthew Harrison | $80 → $81 | Maintains | Equal-Weight | Get Alert |
| 02/03/2023 | Buy Now | 68.54% | Piper Sandler | Do Kim | $111 → $112 | Maintains | Overweight | Get Alert |
| 01/24/2023 | Buy Now | 20.39% | Morgan Stanley | Matthew Harrison | $81 → $80 | Maintains | Equal-Weight | Get Alert |
| 01/19/2023 | Buy Now | 67.04% | Piper Sandler | Do Kim | $104 → $111 | Maintains | Overweight | Get Alert |
| 01/18/2023 | Buy Now | 26.41% | Barclays | Carter Gould | $76 → $84 | Maintains | Equal-Weight | Get Alert |
| 01/03/2023 | Buy Now | 35.44% | Wells Fargo | Mohit Bansal | $75 → $90 | Maintains | Equal-Weight | Get Alert |
| 01/03/2023 | Buy Now | 30.92% | RBC Capital | Brian Abrahams | → $87 | Downgrade | Outperform → Sector Perform | Get Alert |
| 12/13/2022 | Buy Now | 27.91% | B of A Securities | Geoff Meacham | → $85 | Reinstates | → Neutral | Get Alert |
| 12/01/2022 | Buy Now | 21.89% | Morgan Stanley | Matthew Harrison | $68 → $81 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | Buy Now | 35.44% | Cowen & Co. | Tyler Van Buren | $80 → $90 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | 32.43% | Mizuho | Salim Syed | $75 → $88 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 21.89% | SVB Leerink | David Risinger | $68 → $81 | Maintains | Market Perform | Get Alert |
| 10/31/2022 | Buy Now | 38.45% | Maxim Group | Jason McCarthy | $84 → $92 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | 14.37% | Barclays | Carter Gould | $60 → $76 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 2.33% | Morgan Stanley | Matthew Harrison | $67 → $68 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 23.4% | RBC Capital | Brian Abrahams | $79 → $82 | Maintains | Outperform | Get Alert |
| 10/28/2022 | Buy Now | 12.86% | Wells Fargo | Mohit Bansal | $74 → $75 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 44.47% | Piper Sandler | Do Kim | $79 → $96 | Upgrade | Neutral → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 36.94% | Truist Securities | Robyn Karnauskas | $76 → $91 | Upgrade | Hold → Buy | Get Alert |
| 10/13/2022 | Buy Now | 0.83% | Morgan Stanley | Matthew Harrison | $65 → $67 | Maintains | Equal-Weight | Get Alert |
| 10/12/2022 | Buy Now | -9.71% | Barclays | Carter Gould | $56 → $60 | Maintains | Underweight | Get Alert |
| 10/04/2022 | Buy Now | 20.39% | JP Morgan | Chris Schott | $72 → $80 | Upgrade | Neutral → Overweight | Get Alert |
| 09/15/2022 | Buy Now | 14.37% | Truist Securities | Robyn Karnauskas | $71 → $76 | Maintains | Hold | Get Alert |
| 09/13/2022 | Buy Now | 11.36% | Wells Fargo | Mohit Bansal | $63 → $74 | Maintains | Equal-Weight | Get Alert |
| 07/26/2022 | Buy Now | 6.84% | Piper Sandler | Do Kim | $69 → $71 | Maintains | Neutral | Get Alert |
| 07/15/2022 | Buy Now | -2.18% | Morgan Stanley | Matthew Harrison | $63 → $65 | Maintains | Equal-Weight | Get Alert |
| 07/13/2022 | Buy Now | 5.34% | Cantor Fitzgerald | Olivia Brayer | → $70 | Initiates | → Neutral | Get Alert |
| 05/23/2022 | Buy Now | 2.33% | SVB Leerink | David Risinger | → $68 | Initiates | → Market Perform | Get Alert |
| 05/17/2022 | Buy Now | 3.83% | Piper Sandler | Do Kim | $73 → $69 | Maintains | Neutral | Get Alert |
| 04/29/2022 | Buy Now | -5.19% | BMO Capital | Evan Seigerman | $65 → $63 | Maintains | Market Perform | Get Alert |
| 04/29/2022 | Buy Now | 9.85% | Piper Sandler | Do Kim | $72 → $73 | Maintains | Neutral | Get Alert |
| 04/12/2022 | Buy Now | -5.19% | Morgan Stanley | Matthew Harrison | $69 → $63 | Maintains | Equal-Weight | Get Alert |
| 04/12/2022 | Buy Now | 15.87% | RBC Capital | Brian Abrahams | $76 → $77 | Maintains | Outperform | Get Alert |
| 04/04/2022 | Buy Now | 6.84% | Piper Sandler | Do Kim | $77 → $71 | Maintains | Neutral | Get Alert |
| 03/22/2022 | Buy Now | -5.19% | Wells Fargo | Mohit Bansal | $70 → $63 | Maintains | Equal-Weight | Get Alert |
| 03/10/2022 | Buy Now | -15.73% | Barclays | Carter Gould | $63 → $56 | Maintains | Underweight | Get Alert |
| 03/08/2022 | Buy Now | 15.87% | RBC Capital | Brian Abrahams | $85 → $77 | Maintains | Outperform | Get Alert |
| 02/28/2022 | Buy Now | -2.18% | BMO Capital | Evan Seigerman | $75 → $65 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/08/2022 | Buy Now | 12.86% | Mizuho | Salim Syed | $81 → $75 | Maintains | Buy | Get Alert |
| 02/02/2022 | Buy Now | 3.83% | Morgan Stanley | Matthew Harrison | $72 → $69 | Maintains | Equal-Weight | Get Alert |
| 01/28/2022 | Buy Now | 12.86% | Argus Research | David Toung | → $75 | Upgrade | Hold → Buy | Get Alert |
| 01/18/2022 | Buy Now | 8.35% | Morgan Stanley | Matthew Harrison | $74 → $72 | Maintains | Equal-Weight | Get Alert |
| 01/06/2022 | Buy Now | 11.36% | Morgan Stanley | Matthew Harrison | $84 → $74 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/09/2021 | Buy Now | 8.35% | Wells Fargo | Mohit Bansal | — | Initiates | → Equal-Weight | Get Alert |
| 12/06/2021 | Buy Now | 20.39% | Goldman Sachs | Salveen Richter | — | Initiates | → Neutral | Get Alert |
| 10/29/2021 | Buy Now | 12.86% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
| 10/12/2021 | Buy Now | 26.41% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
| 07/30/2021 | Buy Now | 26.41% | RBC Capital | Brian Abrahams | — | Maintains | Outperform | Get Alert |
| 07/30/2021 | Buy Now | 15.87% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
FAQ
Gilead Sciences (GILD) 주식의 목표가는 얼마인가요?
Gilead Sciences (NASDAQ:GILD)의 최신 목표 주가는 7월 1, 2024에 RBC Capital에 의해 보고되었습니다. 이 애널리스트 기관은 $74.00에 대한 가격 목표를 설정했으며, 12개월 이내에 GILD이(가) rise될 것으로 예상합니다 (가능한 11.36% upside). 지난 1년간 34개의 애널리스트 기관이 평가를 보고했습니다.
Gilead Sciences (GILD)에 대한 가장 최근의 애널리스트 평가는 무엇인가요?
Gilead Sciences (NASDAQ:GILD)에 대한 최신 애널리스트 평가는 RBC Capital에 의해 제공되었으며, Gilead Sciences은(는) sector perform 평가를 재강조했다합니다.
Gilead Sciences (GILD)에 대한 마지막 업그레이드는 언제 있었나요?
Gilead Sciences Inc에 대한 마지막 업그레이드는 4월 24, 2024에 발생했습니다. 이 때 HSBC는 $69로 가격 목표를 올렸습니다. HSBC는 이전에 Gilead Sciences Inc에 대해 a reduce를 가지고 있었습니다.
Gilead Sciences (GILD)에 대한 마지막 다운그레이드는 언제 있었나요?
Gilead Sciences Inc에 대한 마지막 다운그레이드는 2월 22, 2024에 발생했습니다. 이 때 Truist Securities가 Gilead Sciences Inc에 대해 가격 목표를 $91에서 $82로 변경했습니다.
Gilead Sciences (GILD)에 대한 다음 애널리스트 평가는 언제 게시 또는 업데이트될 예정인가요?
애널리스트들은 주식 평가를 내리기 위해 철저한 연구를 진행합니다. 이 연구에는 공개된 재무 보고서를 검토하고, Gilead Sciences의 경영진 및 고객과 대화하며, 실적 회의 통화를 듣는 것이 포함됩니다. 대부분의 애널리스트들은 이를 매 분기마다 수행하므로, 한 해에는 회사당 애널리스트 당 4번의 평가를 받을 수 있습니다. Gilead Sciences에 대한 마지막 평가는 7월 1, 2024에 제출되었으므로, 다음 평가가 7월 1, 2025쯤에 제공될 것으로 예상됩니다.
애널리스트 평가 Gilead Sciences (GILD)가 올바른가요?
평가는 주관적이며 변할 수 있지만, 최신 Gilead Sciences (GILD) 평가는 재강조했다로, 가격 목표는 $74.00에서 $74.00으로 조정되었습니다. 현재 Gilead Sciences (GILD)의 가격은 $66.45로, 이는 애널리스트의 예측 범위에서 out of입니다.
검색 애널리스트 평가 및 가격 목표 모든 주식에 대한
사람들이 또한 지켜본다
© 2024 Benzinga | All Rights Reserved